Acrivon Therapeutics, Inc.

"We are pleased that the FDA has granted our ACR-368 OncoSignature test a Breakthrough Device Designation for patients with endometrial cancer. Our AP3-derived ACR-368 OncoSignature test is developed specifically to predict tumor sensitivity to ACR-368 and is used prospectively on pretreatment tumor biopsies in our advancing registrational-intent clinical study. This is the second such designation for our ACR-368 OncoSignature assay and represents yet another powerful validation of our generative AI-driven AP3 platform,” said our CEO Peter Blume-Jensen. Read the PR: https://lnkd.in/e8T_aMnH

Our selective, dual WEE1/PKMYT1 inhibitor, ACR-2316, was featured in a presentation at the DDR Inhibitors Summit. David Proia, VP of Biology and Drug Discovery, reviewed how we used our AP3 platform to determine that balanced PKMYT1 inhibition overcomes a dominant cellular WEE1 inhibition-induced resistance mechanism resulting in superior single-agent activity. ACR-2316 is an internally discovered compound and is now in clinical development, having advanced in 15 months from initial lead to Phase 1 trial initiation, uniquely enabled by AP3. Read more about our programs here: https://lnkd.in/g-HDGPNm

We are excited to kick off the new year with a busy schedule of meetings next week in San Francisco and also run into friends and colleagues there!

We are looking forward to our upcoming presentation on ACR-2316, which was rationally designed by AP3 for antitumor activity through potent activation of CDK1, CDK2, and PLK1. This asset was advanced in only 15 months from initial lead to human dosing. Patients are being administered ACR-2316 in an ongoing Phase 1 study in selected solid tumors identified by AP3. Find out more: https://lnkd.in/d8ndNB7q

HUPO is one of the most prestigious proteomics-focused congresses, and we are excited to have data demonstrating AP3’s proprietary and actionable machine learning-driven capabilities for drug discovery and clinical development be featured in two poster presentations. Following the sessions, you will be able to access a copy of the posters on our website at https://lnkd.in/gStqjybY

We are excited to share this program milestone significantly ahead of schedule. ACR-2316 was specifically designed with AP3 to overcome limitations of existing WEE1 and PKMYT1 inhibitors and to exhibit superior single-agent activity as demonstrated in head-to-head preclinical studies against clinical benchmark comparators. Our CEO Peter remarked: “The rapid advancement of ACR-2316 into the clinic was enabled by the powerful capabilities of our AP3 Interactome which leverages machine learning to integrate all in-house AP3 phosphoproteomic drug profiling data yielding actionable insights with direct application for streamlined drug discovery. This progress serves as a testament to the unwavering commitment of the outstanding Acrivon team.” Read more: https://lnkd.in/en6Yfhn9

As #GynecologicCancerAwarenessMonth (#GCAM) comes to a close, our work to develop transformational therapies for these patients continues! To learn more about our ongoing clinical trials, visit our site at https://lnkd.in/ecbEY5KC. For information on gynecologic cancers, you can visit https://igcs.org/ and https://lnkd.in/gSVY_fTN.

“We are very excited to provide several significant, positive updates across our rapidly advancing clinical pipeline since our last R&D event in April,” said CEO Peter Blume-Jensen. Read the release to find out more: https://lnkd.in/e4BurzaG Virtual Investor Event at 9am ET: https://lnkd.in/gBFGjTa6

Join us on Saturday, Sept 14 at 9am ET for a virtual investor event following our ESMO poster presentation of positive ACR-368 clinical data in endometrial cancer. A live and archived webcast will be available here: https://lnkd.in/gBFGjTa6

On Women’s Equality Day, we would like to recognize all of the talented women at Acrivon. From scientists to clinical, finance, legal, business development and human resources professionals (and beyond!), women are key to advancing our mission to successfully developing precision medicines.